Drugs / OPN-6602
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06433947 | Aug 2024 → Jul 2026 overdue | plasma cell myeloma | Opna Bio LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-15 | Opna Bio LLC | Regulatory Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma opnabio.com ↗
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OPN-6602, a dual EP300/CBP inhibitor, for the treatment of multiple myeloma (MM). |
| 2025-02-12 | Opna Bio LLC | Regulatory Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma opnabio.com ↗
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to one of its lead programs, OPN-6602, for the treatment of multiple myeloma (MM). |
| 2024-12-09 | Opna Bio LLC | Results Opna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis opnabio.com ↗
Preclinical data from a second program, OPN-6602, showed significant tumor regression in multiple myeloma models as a single agent and in combination with other therapeutics. |
| 2024-04-10 | Opna Bio LLC | Results Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting opnabio.com ↗
Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPN-6602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06433947 ↗ |
| Action | Inhibit | “inhibitor of EP300 and CBP bromodomain” NCT06433947 ↗ |
| Modality | Small molecule | “orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily” NCT06433947 ↗ |
| Route | Oral | “orally active” NCT06433947 ↗ |
| Target | EP300 | “inhibitor of EP300” NCT06433947 ↗ |